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A B S T R A C T
The aim of this study was to determine the virulence characteristics and resistance pattern of the extended-spectrum b
lactamases (ESBLs)-producing Escherichia coli strains isolated from urine of outpatients in the Zagreb region during a
five-month period, and to compare them with the non ESBLs-producing E. coli strains isolated in the same period. Out
of 2,451 E. coli strains isolated from urine of nonhospitalized patients with significant bacteriuria, a total of 39 ESBLs-
producing strains (1.59%) were detected by a double-disk diffusion technique and by the broth-dilution minimal inhibi-
tory concentration reduction method. The 45 non ESBLs-producing strains were randomly chosen, and phenotype of the
two groups of strains was characterized and compared. Serogroup O4, hemolysin production, expression of P- and type 1
fimbriae as well as resistance to gentamicin and amikacin were significantly more prevalent characteristics among the
ESBLs-producing strains than among non ESBLs-producing strains (p<0.01), while higher prevalence of trimetho-
prim-sulfamethoxazole resistance among ESBLs-producing strains was not statistically significant (p>0.05). Chromo-
somal DNA analysis by pulsed-field gel electrophoresis exhibited a great genomic similarity among ESBLs-producing
strains and revealed that those highly virulent and resistant E. coli strains isolated from urine of outpatients in the
Zagreb region had a clonal propagation.
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nation
Introduction
Recent data indicate that urinary tract infections
caused by extended-spectrum b lactamases (ESBLs)-pro-
ducing Escherichia coli may be an emerging problem in
outpatient settings in various parts of the world. Possible
community-acquisition of ESBLs-producing E. coli was
first reported in 1998 from Ireland when a nalidixic acid
resistant E. coli producing an ESBL was isolated from
urine of an elderly patient who did not have a recent his-
tory of hospitalization1. Since than, ESBLs-producing E.
coli have been increasingly recognized in the commu-
nity2–9.
An interesting issue concerning the epidemiology of
ESBLs-producing organisms is the evolution, mainte-
nance, and dissemination of resistance genes among bac-
terial populations in larger geographic regions10. Zagreb
region has 1,200,000 inhabitants and besides Zagreb
eight smaller towns are included in the region. Zagreb
Institute of Public Health is the biggest regional insti-
tute of public health in Croatia, which collects samples
for microbiological analysis from over 800 general practi-
tioner offices. During a previous survey conducted over a
five-month period in 2004 at the Zagreb Institute of Pub-
lic Health, 39 of 2,451 consecutive, nonredundant E. coli
strains deemed to cause urinary tract infections pro-
duced an ESBL. The aim of this study was to character-
ize those strains isolated from urine of nonhospitalized
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patients, and to compare them with the characteristics of
45 randomly chosen non ESBLs-producing E. coli strains
isolated from urine of nonhospitalized patients in the
same period. The genetic relatedness of the ESBLs-pro-
ducing isolates was analyzed by digesting genomic DNA
with the restriction endonuclease XbaI and by perform-
ing pulse-field gel electrophoresis (PFGE).
Materials and Methods
Bacterial strains – origin and identification: During
the five-month study period (January to May 2004) a to-
tal of 2,451 E. coli strains were isolated from urine of
nonhospitalized patients with significant bacteriuria in
the Department of Microbiology at Zagreb Institute of
Public Health, Zagreb, Croatia. A total of 39 ESBLs-pro-
ducing E. coli strains were detected and collected, as well
as 45 randomly chosen non ESBLs strains. Only one iso-
late per patient was included. The E. coli isolates were
identified by standard biochemical procedures and stored
in deep-agar tubes at 4 °C (1.5% nutrient agar, Difco Lab.,
Detroit, MI, USA) and subcultured on tryptic soy agar
(TSA, Difco Lab., Detroit, MI, USA) before use.
Antibiotic susceptibility testing: Antibiotic susceptibil-
ity testing was performed onMueller-Hinton agar (Oxoid
Ltd., Hampshire, UK) medium by a standard disk diffu-
sion method with a panel of 17 antimicrobial drugs ac-
cording to the recommendations of the National Com-
mittee for Clinical Laboratory Standards11. The tablet
disks contained the following antimicrobial agents: amo-
xicillin, amoxicillin-clavulanic acid, piperacillin, pipera-
cillin-tazobactam, cephalexin, cefuroxime, ceftazidime,
ceftibuten, ceftriaxone, aztreonam, imipenem, gentami-
cin, netilmicin, amikacin, trimethoprim-sulfamethoxa-
zole, ciprofloxacin, and nitrofurantoin. Strains with in-
termediate zones were considered resistant.
ESBL tests: The ESBL production was detected by
double disk diffusion technique. In this test a plate was
inoculated as for a standard disk diffusion test. Disk con-
taining aztreonam and expanded-spectrum cephalospo-
rins were than placed 30 mm from an amoxicillin-clavu-
lanate disk prior to incubation. After overnight incu-
bation at 37 °C the production of ESBLs was detected by
the presence of characteristic distortions of the inhibi-
tion zones indicative of clavulanate potentiation of the
activity of the test drug12. The broth-dilution minimal in-
hibitory concentration (MIC) reduction method was used
as confirmatory test (³3-dilution reduction in the MIC of
cefotaxime or ceftazidime in the presence of clavulanic
acid in concentration of 4 mg/L)13.
Serogroup determination: All E. coli isolates were
serotyped using 17 different O-antisera (Institute of Im-
munology, Zagreb, Croatia), These O types (O1, O2, O4,
O5, O6, O7, O8, O9, O11, O15, O17, O18, O20, O25, O50,
O62 and O75) were selected because of their frequent oc-
currence as urinary pathogens. Serotyping was perfor-
med on glass slides and confirmed using a mechanized
microtechnique14.
Hemolytic activity: The production of a hemolysin
was tested on human blood agar plates. The bacteria
growing on TSA were stabbed with a sterile straight wire
into 5% human blood agar. After 18 to 24 h of incubation
at 37 °C, the clearing zone was observed.
Adhesins determination: The expression of adhesins
was defined by hemagglutination and inhibition of he-
magglutination in microtiter plates, as previously descri-
bed15,16. Briefly, hemagglutination (HA) was performed
using human erythrocytes and sheep, ox and guinea pig
erythrocytes. Inhibition of HA was performed with P1
antigen-containing pigeon egg white and with D-man-
nose (Sigma Chemical Co., St. Louis, USA), as previously
described15,17. Isolates were considered to express P-fim-
briae if HA was positive with human erythrocytes and in-
hibition of HA was positive with pigeon egg white, which
was confirmed by agglutination of receptor-coated latex
beads. The type 1 fimbriae were considered to be ex-
pressed if HA was positive with guinea pig erythrocytes.
D-mannose always inhibited HA of guinea pig erythro-
cytes (mannose sensitive, MS HA), but it never inhibited
HA of human, ox or sheep erythrocytes (mannose resis-
tant, MR HA).Strains with MR HA ability and without
detected P-specificity was considered to express X adhe-
sin, and strains which agglutinated sheep and human
blood group A erythrocytes, but did not agglutinate hu-
man blood group 0 erythrocytes, were considered to ex-
press 0NAP adhesin.
Sera and serum sensitivity assay: Blood was obtained
by venipuncture from three healthy volunteers and was
allowed to clot at room temperature for 30 min and over-
night at 4 °C. After centrifugation at 1000 g for 15 min at
4 °C, serum was removed and pooled. A portion of the
pooled serum was decomplemented by heating at 56 °C
for 30 min and used as test controls. Bacterial suscepti-
bility to serum killing was measured by assessing re-
growth after incubation in normal human serum accord-
ing to Schiller and Hatch method18. Briefly, after adjust-
ment of each bacterial suspension to a concentration
equivalent to the concentration of 103 bacteria/mL, the
mixture of 0.1 mL of bacterial suspension and 0.1 mL of
pooled fresh human serum were incubated at 37 °C for
two hours. Finally, the percent bacterial survival was de-
termined by plating 0.1 mL samples onto Mueller-Hin-
ton agar plates and the number of bacteria per milliliter
was determined after incubation at 37 °C for 18–24 hours
and compared to control which contained mixture of bac-
terial suspension and decomplemented serum. The bac-
terial strain was determined as serum sensitive (SS) if
there were more than 90 percent killed bacteria regarded
to serum action. Opposite, if there were less or equal to
90 percent killed bacteria, bacterial strain was deter-
mined as serum resistant (SR).
DNA macrorestriction and PFGE: Genomic DNA was
prepared by a protocol devised from different methods
published elsewhere19,20. Cleavage of the agarose-embed-
ded DNA was achieved with 0.2 U/mL XbaI (Invitrogen)
according to instructions of the manufacturer. PFGE was
performed in the CHEF DRII System (Bio-Rad, Rich-
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mond, CA, USA) under the following conditions: 0.5 x
TBE, 1% agarose, 12 °C, 6 V/cm. Run times and pulse
times were 5–50 s for 22 h with linear ramping. The gels
were stained with ethidium bromide (1 mg/mL) and pho-
tographed under UV light. The PFGE patterns were
compared initially by visual comparison according to the
guidelines of Tenover et al.21. Patterns were considered
indistinguishable if every band was shared, closely re-
lated if they differed from one another by only three or
fewer clearly visible bands, possibly related if they dif-
fered by 4–6, and different if they differed by seven or
more bands. PFGE patterns were also analyzed with the
GelCompar II computer software (Applied Maths, Sint-
Martns-Latem, Belgium). Cluster analysis of the Dice
similarity coefficients based on the unweighted pair group
method using arithmetic averages was done to generate a
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TABLE 1
CHARACTERISTICS OF 39 ESBLS-PRODUCING E. COLI STRAINS
Isolate
No.
Age/ Gendera Resistotype b Serogroupc Adhesins d Hemolysin SBA e
1 34/ f NF NT P fimbriae + SS
2 65/ f SXT NT HA=0 – SS
3 76/ f SXT, NF NT X+type 1 fimbriae – SS
4 30/ m / O4 P+type 1 fimbriae + SS
5 41/ f / O4 P+type 1 fimbriae + SS
6 2/ f Gm, NET, AK O6 type 1 fimbriae + SS
7 60/ f / O4 P+type 1 fimbriae + SS
8 15/ f Gm, AK O4 P+type 1 fimbriae + SS
9 50/ f Gm, AK, SXT O4 P+type 1 fimbriae + SR
10 1/ f Gm, AK, SXT O4 P+type 1 fimbriae + SS
11 28/ f Gm, SXT O4 P+type 1 fimbriae + SR
12 26/ f Gm, NET, AK O4 P+type 1 fimbriae + SS
13 78/ f Gm, NET, AK, PTZ O4 P+type 1 fimbriae + SS
14 1/ m Gm, AK O4 P+type 1 fimbriae + SS
15 79/ f Gm, NET, AK O4 P+type 1 fimbriae + SS
16 1/ f Gm, AK O4 P+type 1 fimbriae + SS
17 50/ f Gm, AK O4 P+type 1 fimbriae + SR
18 1/ f Gm, AK O4 P+type 1 fimbriae + SS
19 3/ m Gm, AK O4 P+type 1 fimbriae + SS
20 25/ f Gm, NET, AK O4 P+type 1 fimbriae + SS
21 74/ f / O4 P+type 1 fimbriae + SS
22 1/ m Gm,AK O4 P+type 1 fimbriae + SR
23 30/ f Gm, AK O4 P+type 1 fimbriae + SR
24 39/ f Gm, AK O4 P+type 1 fimbriae + SR
25 52/ f Gm, SXT, NF, CIP O6 HA=0 – SR
26 39/ f AMC, SXT, CIP O1 HA=0 – SS
27 58/ f Gm, AK O4 P+type 1 fimbriae + SS
28 36/ f Gm, AK O4 P+type 1 fimbriae + SR
29 29/ f Gm, NET, AK O4 P+type 1 fimbriae + SR
30 77/ f Gm, NET, AK O15 HA=0 – SS
31 73/ f Gm, NET, NF O4 HA=0 – SS
32 2/ f Gm, NET, AK O6 type 1 fimbriae + SS
33 52/ f Gm, SXT, NF, CIP O6 HA=0 – SR
34 1/ m Gm NT HA=0 – SR
35 49/ m Gm, AK O4 P+type 1 fimbriae – SR
36 40/ f Gm, NET, AK O6 P+type 1 fimbriae + SS
37 70/ m NF, CIP O4 type 1 fimbriae – SS
38 67/ f Gm, AK, SXT NT HA=0 – SS
39 55/ m Gm, AK NT P+type 1 fimbriae + SS
a m – masculine, f – feminine, b Gm – gentamicin, NET – netilmicin, AK – amikacin, AMC – amoxicillin-clavulanate, PTZ – piperacillin-
tazobactam, SXT – trimethoprim-sulfamethoxazole, FM – nitrofurantoin, CIP – ciprofloxacin, c NT – nontypeable strain, d HA=0 –
nonagglutinating strain, e SS – serum sensitive, SR – serum resistant
dendrogram describing the relationship among E. coli
pulsotypes. Isolates were considered to be identical if
they showed 100% similarity and were considered clo-
nally related if they showed greater than 80% similarity
(comparable to the three or fewer fragment difference al-
ready noted).
T. Marijan et al: Emergence of ESBLs-producing E. coli, Coll. Antropol. 31 (2007) 1: 227–233
230
TABLE 2
CHARACTERISTICS OF 45 NON ESBLS-PRODUCING E. COLI STRAINS
Isolate No. Age/ Gendera Resistotype b Serogroup c Adhesins d Hemolysin SBA e
1 52/ f AMX, CN O75 X+type 1 fimbriae + SR
2 52/ f / NT HA=0 – SS
3 27/ f / O18 X adhesin + SR
4 72/ f AMX, SXT O17 X adhesin – SS
5 54/ m AMX O2 P fimbriae + SS
6 61/ f / O1 0NAP adhesin – SR
7 55/ f / O1 X adhesin – SS
8 77/ f AMX, NF NT HA=0 – SS
9 73/ f / O15 X adhesin – SS
10 73/ f AMX O9 X adhesin – SS
11 89/ f AMX, SXT NT P fimbriae – SS
12 71/ f / O2 P fimbriae + SS
13 7 / m AMX O6 HA=0 + SS
14 65/ f AMX, SXT NT type 1 fimbriae – SS
15 56/ f / O2 P+type 1 fimbriae + SR
16 93/ f / O2 HA=0 – SS
17 34/ f CN O6 HA=0 + SR
18 61/ f CN O25 HA=0 – SR
19 26/ f AMX O18 P+type 1 fimbriae + SR
20 61/ f SXT O2 P+type 1 fimbriae + SR
21 81/ f AMX O18 P fimbriae + SR
22 81/ f AMX, SXT NT P fimbriae – SS
23 21/ f / O6 X adhesin + SR
24 32/ f / O2 P+type 1 fimbriae + SR
25 42/ m / O6 HA=0 + SR
26 16/ f / O75 X+type 1 fimbriae + SR
27 56/ f / O18 HA=0 – SR
28 74/ m / O2 HA=0 – SS
29 33/ f CIP O17 HA=0 – SS
30 80/ f / O2 HA=0 – SR
31 71/ f / NT P fimbriae – SS
32 ? / f / NT type 1 fimbriae + SR
33 34/ f / NT P+type 1 fimbriae – SR
34 37/ f SXT O25 X+type 1 fimbriae + SR
35 32/ f / NT HA=0 – SS
36 67/ f / O7 X adhesin – SR
37 53/ f CN O75 X+type 1 fimbriae + SR
38 78/ m / NT X adhesin – SR
39 54/ f AMX NT type 1 fimbriae – SR
40 81/ f / NT HA=0 – SS
41 68/ f / NT HA=0 – SS
42 80/ f / NT P fimbriae + SS
43 77/ m AMX NT HA=0 – SR
44 75/ f / O18 type 1 fimbriae – SR
45 78/ f AMX, CN, SXT NT type 1 fimbriae – SR
a m – masculine, f – feminine, bAMX – amoxicillin, CN – cephalexin, SXT – trimethoprim-sulfamethoxazole, NF – nitrofurantoin, CIP –
ciprofloxacin, c NT – nontypeable strain, d HA=0 – nonagglutinating strain, 0NAP – 0 negative A positive, e SS – serum sensitive, SR –
serum resistant
Statistical methods: Proportions were compared by
the c2-test and by Fisher’s exact test when the number in
any of the 2x2 table was 5. A p-value <0.01 was consid-
ered statistically significant.
Results
The characteristics of 39 community-acquired ESBLs-
producing E. coli strains isolated in the 5-month study
period are presented in Table 1. Among 39 ESBLs-pro-
ducing strains tested, co-resistance to various antimicro-
bial agents was observed in 35 strains, such as resistance
to gentamicin, netilmicin, amikacin, piperacillin-tazo-
bactam, trimethoprim-sulfamethoxazole, nitrofurantoin,
and ciprofloxacin. The co-resistance to gentamicin was
the most frequently observed, followed by resistance to
amikacin, netilmicin and trimethoprim-sulfamethoxazo-
le. The most frequently detected serogroup was O4, de-
tected in 26 out of 39 investigated strains. High virulence
capacity of the strains based on adhesins expression and
hemolytic activity was observed, and 28 strains produced
a hemolysin, 27 strains expressed P-fimbriae, while 30
strains expressed type 1 fimbriae. In only eight strains
adhesins expression was not detected. Most strains (27)
were sensitive to bactericidal activity of normal human
serum, and were isolated from urine of female patients.
The 8 male and 31 female patients ranged in age from 1
to 79 years (median age 39 years).
The characteristics of 45 randomly chosen non ESBLs-
producing E. coli strains isolated from urine of nonhospi-
talized patients in the same period are presented in Ta-
ble 2. Most strains were sensitive to all antibiotics tested,
while 14 strains were resistant to amoxicillin and seven
to trimethoprim-sulfamethoxazole. There was no signifi-
cantly higher frequency among serogroups distribution,
and 16 strains were not typeable with the diagnostic sera
used. Type 1 fimbriae were expressed in 14 strains, P
fimbriae in 12 strains, and in15 strains adhesins were
not detected. Hemolysin production was observed in 18
strains, and 25 strains were resistant to serum bacteri-
cidal activity. The strains were isolated from urine of six
male and 39 female patients ranged in age from 7–93
years (median age 58 years).
Molecular characterization of 39 ESBLs-producing
strains performed by PFGE revealed genetic relatedness
between 25 strains (>80% similarity). After the extrac-
tion of genomic DNA and digestion with XbaI restriction
enzyme, the PFGE fingerprints exposed the existence of
two clusters (Figure 1), which were closely related, re-
sulting in one to three band differences (the Dice similar-
ity coefficient, Dsc. 83.49%). The first cluster was com-
posed of 11 strains (85.48% of similarity) and the second
cluster was composed of 14 strains (87.99% of similar-
ity). The rest of 14 ESBLs-producing strains tested were
not clonally related (Dsc. <80%, Figure 1).
Serogroup O4, hemolysin production, expression of P-
and type 1 fimbriae as well as resistance to gentamicin
and amikacin were significantly more prevalent charac-
teristics among the ESBLs-producing strains than among
non ESBLs-producing strains (p<0.01), while higher
prevalence of trimethoprim-sulfamethoxazole resistance
among ESBLs-producing strains was not statistically sig-
nificant (p>0.05, Table 3). The difference in serum sensi-
tivity between the two groups of strains was not statisti-
cally significant as well (p>0.01).
Discussion
The present study demonstrated clonal dissemination
of highly virulent ESBLs-producing E. coli strains iso-
lated from urine of nonhospitalized patients in a large,
well defined region in Croatia. Preliminary results of mo-
lecular characterization have shown production of SHV
class of ESBL, and further analysis follows (data not pre-
sented).
Although urinary tract infection is not usually thought
of as a disease associated with community-wide out-
breaks, certain multidrug-resistant, uropathogenic lin-
eages of E. coli have exhibited epidemic behavior22. E.
coli O15:K52:H1 caused an outbreak of community-ac-
quired cystitis, pyelonephritis, and septicemia in south
London, England in 1986 to 1987, when strains of this
serotype expressed P fimbriae, produced aerobactin, and
displayed an unusual multiple antimicrobial resistance
phenotype22. The subsequent recognition of O15:K52:H1
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Fig. 1. Dendrogram and PFGE fingerprints of 39 ESBL-produc-
ing E.coli isolates after digestion with XbaI restriction enzyme.
The Dice similarity coefficient (Dsc.) for strains 21, 15, 14, 28,
18, 20, 4, 13, 7, 5, 12, 24, 22, 19, 35, 8, 9, 16, 29, 39, 10, 23, 17, 27
and 1183.49%. Other strains are not clonally related (Dsc.<80%).
as the second most common serotype among E. coli
bacteriemia isolates at a Copenhagen hospital (origi-
nated from urinary tract), together with the observation
that Copenhagen isolates exhibited the same virulence
factors as the south London outbreak strains, provided
further evidence of the pathogenic potential of E. coli
O15:K52:H1 and suggested that this serotype might con-
stitute a widespread virulent clone23. This was confirmed
by the findings from Spain, which indicated that E. coli
O15:K52:H1 constitutes a broadly distributed and clini-
cally significant uropathogenic clone with fluid antimi-
crobial resistance capabilities, and is an endemic cause of
urinary tract infection in Barcelona24. In 2001 Manges
and coworkers reported that a single clonal group ac-
counted for nearly half of community-acquired urinary
tract infections in women that were caused by E. coli
strains with resistance to trimethoprim-sulfamethoxa-
zole in three geographically diverse communities in the
United States of America25. Subsequently, those strains
were signated as a clonal group A (CGA) and it was found
that they exhibit a robust virulence profile suggesting
enhanced extraintestinal virulence26,27. Johnson and co-
workers concluded that this combination of resistance
and virulence may account for CGA’s recent emergence
as a broadly disseminated epidemic clone26. In the pres-
ent study, the observed high virulence of clonally related,
multiresistant E. coli strains isolated from urine of non-
hospitalized patients in the Zagreb region causes concern
and requires additional surveillance of the clone spread
in the community.
A number of risk factors have been identified as
linked with the acquisition of community-acquired infec-
tions involving ESBLs-positive isolates. Mostly, a previ-
ous hospitalization or antibiotic therapy within the pre-
vious three months, old age (>60 years), male gender,
confinement to bed with debilitation and urinary cathe-
terization were detected as risk factors28,29. In the pres-
ent study, females had significantly higher rates of acqui-
sition of ESBLs-producing E. coli strains and median age
of patients was only 39 years. Moreover, patients were
not institutionalized and lived in different parts of the
region. Limitations of the study include the paucity of
clinical and epidemiological data, therefore no conclu-
sions about risk factors, spread or origin of the strains
can not be made. Further studies are warranted to inves-
tigate whether community-onset urinary tract infections
caused by ESBLs-producing, highly virulent E. coli strains
are related to a point source, or transmission within the
community. Recent intriguing hypothesis suggests possi-
bility that multidrug-resistant, uropathogenic E. coli
strains may be spread by contaminated food products30.
Conclusion
PFGE highlighted that highly virulent uropathogenic
ESBLs-producing E. coli strains isolated from outpa-
tients in Zagreb region had a clonal propagation. Further
molecular characterization of those strains is needed, as
well as the additional epidemiological studies of the strains
origin and spread in the community.
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POJAVA UROPATOGENIH SOJEVA BAKTERIJE ESCHERICHIA COLI KOJI PRODUCIRAJU
b LAKTAMAZE PRO[IRENOG SPEKTRA U ZAJEDNICI
S A @ E T A K
Cilj ovog istra`ivanja bio je utvrditi virulentne zna~ajke i rezistotip sojeva bakterije Escherichia coli koji produciraju
b laktamaze pro{irenog spektra, izoliranih iz mokra}e ambulantnih pacijenata zagreba~ke regije u razdoblju od pet
mjeseci, i usporediti ih sa sojevima E. coli koji ne stvaraju b laktamaze pro{irenog spektra, a izolirani su u istom razdo-
blju. Od 2451 E. coli sojeva izoliranih iz mokra}e izvanbolni~kih pacijenata sa signifikantnom bakteriurijom, ukupno
39 sojeva produciralo je b laktamaze pro{irenog spektra (1,59%), {to je detektirano metodom dvostruke disk-difuzije i
metodom redukcije minimalne inhibicijske koncentracije u bujonu. Slu~ajnim odabirom prikupljeno je 45 sojeva koji ne
produciraju b laktamaze pro{irenog spektra, te je odre|en i uspore|en fenotip ove dvije grupe sojeva. Najzastupljenije
zna~ajke sojeva koji su producirali b laktamaze pro{irenog spektra bile su serogrupa O4, produkcija hemolizina, ispo-
ljavanje P i tip 1 fimbrija, te rezistencija na gentamicin i amikacin (p<0,01), dok ve}a zastupljenost rezistencije na
trimetoprim-sulfametoksazol nije bila statisti~ki zna~ajna (p>0,05). Kromosomska DNA analiza pomo}u gel-elektro-
foreze u izmjeni~nom polju pokazala je veliku genetsku sli~nost me|u sojevima koji produciraju b laktamaze pro{irenog
spektra i otkrila klonalno {irenje ovih visoko virulentnih i rezistentnih uropatogenih sojeva E. coli me|u izvanbolni-
~kim pacijentima zagreba~ke regije.
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